BioCentury | Mar 15, 2019
Product Development

Fresh AIMMs for elite responders

...CD9 with an abnormal post-translational modification: excessive palmitoylation. The antibody became the basis for AIMM’s AT1412...
...and subsequently raised a $25 million series A round from an undisclosed investor to bring AT1412...
...the mAbs’ mechanisms of action against tumor-specific post-translational modifications on target proteins. The company found AT1412’s...
BioCentury | Apr 3, 2014
Financial News

Scynexis amends IPO again

Scynexis Inc. (Research Triangle Park, N.C.) again amended its IPO and now plans to sell 7.3 million shares at $7-$8. At the $7.50 midpoint, the company would raise $55 million and be valued at $141.2...
BioCentury | Oct 24, 2011
Financial News

Ligand financial update

Ligand filed a shelf registration covering the sale of up to $30 million of its securities. The company, which closed Friday at $14.12, has 20.8 million shares outstanding. Ligand Pharmaceuticals Inc. (NASDAQ:LGND), La Jolla, Calif....
BioCentury | Jun 25, 2001
Finance

Ebb & Flow

The $66.6 million raised by four European companies last week may have looked paltry compared to the $895 million raised in the U.S. But the week's biggest deal, the £25 million ($35.1 million) IPO in...
BioCentury | Jun 25, 2001
Finance

Ebb & Flow

The $66.6 million raised by four European companies last week may have looked paltry compared to the $895 million raised in the U.S. But the week's biggest deal, the £25 million ($35.1 million) IPO in...
Items per page:
1 - 5 of 5